Uncategorized
VIDEO: Patients with AMD and resolved PED at 24 months at higher risk of developing macular atrophy
DENVER — At the Association for Research in Vision and Ophthalmology meeting here, Arshad Khanani, MD, discusses a subgroup analysis of patients being treated with ranibizumab for wet-AMD with differing degrees of pigment epithelial detachment at 24 months of treatment. Among the findings of the study, Khanani found a three-times greater risk of macular atrophy in those patients whose PED had completely resolved at 24 months, than those patients who still had persistent PED at 24 months.